TG Therapeutics Inc Stock - TGTX Share Price Today, News and Discussion

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Sector:

Health Technology

Industry:

Pharmaceuticals Major

Employees:

286

Current Price	$18.89
Prev Close	$18.48
Open	$18.73
Dividend Yield	0.00%
50-Day Moving Average	$10.59
Beta	1.91
Avg. Volume	5.5M
PE Ratio	N/A

52-Week High	$18.16
52-Week Low	$3.48
Market Capitalization	$2.61B
EPS	-$1.78
Price to Book	26.00
Revenue Per Employee	$17,569.93
Enterprise Value/EBITDA	-3.03

No TGTX news at the moment.

TGTX TG Therapeutics Inc

About

Feed

Fundamentals

News